Obstructive Lung Disease
In adult-diagnosed cystic fibrosis, diabetes, lung function, and age at diagnosis may predict patient survival.
The approval was based on data from a 24-week, open-label, Phase 3 study in patients aged 2 to 5 years.
A higher prevalence of anaerobic bacteria in cystic fibrosis was associated with higher lung function, less use of antibiotics, increased BMI, pancreatic sufficiency, and no requirement for insulin.
Results of a pooled analysis of cross-sectional studies demonstrated an increase in cough, sputum production, wheezing, and dyspnea from marijuana use.
Compared with placebo, the risk for a pulmonary exacerbation was reduced by 44% in participants with cystic fibrosis who received azithromycin.
Bronchiectasis-associated genera included Aspergillus, Cryptococcus, Clavispora, Botrytis, and Alternaria.
Ivacaftor decreased the risk for death, transplantation, hospitalization, and pulmonary exacerbation in patients with cystic fibrosis.
Sputum viscoelastic properties were associated with lung function and disease status in patients with cystic fibrosis.
Proteostasis Therapeutics is developing the combination treatment which includes a novel transmembrane conductance regulator (CFTR) amplifier (PTI-428), a third generation corrector (PTI-801) and a potentiator (PTI-808).
Patients with cystic fibrosis who took azithromycin had a significantly lower risk for detection of new nontuberculous mycobacteria, methicillin-resistant Staphylococcus aureus, and Burkholderia cepacia complex.
CFTR modulator therapy recommended in certain patients with cystic fibrosis.
Effective cystic fibrosis transmembrane conductance regulator modulator therapy may be of benefit in subsets of patients with cystic fibrosis.
Palliative care access may be limited for patients with cystic fibrosis.
The Adult ADHD Self-Report Scale-v1.1 Symptom Checklist may be able to detect previously undiagnosed ADHD in patients with cystic fibrosis.
Data from 200 participants were analyzed to determinet he link between sleep disordered breathing, cognitive function, and cognitive impairment.
Lower microbial diversity in the respiratory tract in patients with cystic fibrosis was linked with prophylactic antibiotics and less airway inflammation.
Sweat chloride can predict severity in patients with CF, especially for long-term lung damage.
Combination lumacaftor/ivacaftor therapy was found to be safe and effective in patients with cystic fibrosis aged 6 to 11 years.
Statin therapy reduces inflammation and improves quality of life in patients with severe bronchiectasis infected with P aeruginosa.
Patients with persistent hypercapnia following acute exacerbation of COPD, home noninvasive ventilation with home oxygen therapy prolonged readmission time.
The rise in asthma and allergy symptoms may be due to climate change which heightens the damage of airway cells by outdoor fungus.
The release of a new autonomous approach for terminating the COPD crisis has been lead by the National Heart, Lung and Blood Institute (NHLBI).
Researchers examined the relationship between COPD and right and left ventricular morphometry to determine which patients may better respond to beta-blocker therapies.
The FDA has expanded the approved indication of ivacaftor for cystic fibrosis, increasing the number of rare gene mutations the drug may be used to treat.